Davis R M Inc. Lowers Stock Position in IDEXX Laboratories, Inc. $IDXX

Davis R M Inc. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,963 shares of the company’s stock after selling 1,520 shares during the period. Davis R M Inc. owned about 0.12% of IDEXX Laboratories worth $51,673,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of IDXX. Empowered Funds LLC boosted its position in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories during the second quarter worth about $265,000. Jump Financial LLC grew its position in IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after buying an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $164,000. Finally, Sei Investments Co. boosted its stake in shares of IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on IDXX shares. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $545.00 on Thursday. The company has a 50-day simple moving average of $555.83 and a 200-day simple moving average of $596.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The company has a market cap of $42.99 billion, a PE ratio of 40.13, a price-to-earnings-growth ratio of 3.02 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.